MedTrace Logo

Acupuncture/Moxibustion for Peripheral Neuropathy in HIV

NCT00317291 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-09-11

No results posted yet for this study

Summary

This is a sample-size-limited, randomized, blinded (subject and evaluator), sham acupuncture/placebo moxibustion (sham acu/placebo moxa) controlled clinical trial. The subjects in this study will be 50 men and women with HIV infection who have a diagnosis of distal symmetric peripheral neuropathy (DSP). Subjects will be randomized to one of two experimental intervention conditions:

* Condition 1: subjects receive acu/moxa treatment; and
* Condition 2 (Control Group): subjects receive sham acu/placebo moxa.

All subjects in Conditions 1 and 2 will attend 16 scheduled sessions over 15 weeks, be administered the same instruments, and submit their daily symptom diaries for analysis. There will be six weeks of twice weekly treatment sessions, and three follow-up sessions at weeks 9, 11, and 15. All conditions will be identical in duration and be administered by licensed acupuncturists trained in traditional Chinese medicine (TCM).

Conditions

  • Peripheral Neuropathies
  • HIV Infections

Interventions

PROCEDURE

Acupuncture/Moxibustion

Acupuncture/Moxibustion: 16 scheduled sessions

OTHER

Sham acupuncture/Placebo moxibustion

Sham acupuncture/Placebo moxibustion: 16 scheduled sessions

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    lead NIH

Principal Investigators

  • Joyce K Anastasi, PhD, DrNP · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00317291 on ClinicalTrials.gov